Axsome Therapeutics is Looking Forward to Significant Market Launches and FDA Approvals – Wells Fargo Sees 40% Potential!

Axsome Therapeutics (AXSM) aims to reach over 150 million people in the USA with treatment solutions for central nervous system (CNS) disorders and has the potential to achieve a peak revenue of $16.5 billion with its approved products and a promising pipeline. The antidepressant Auvelity is currently the key growth driver, with a growth rate of 80% and accounting for over 79% of total revenues in Q1. CEO Herriot Tabuteau recently highlighted significant progress in the late-stage wide pipeline. Auvelity could receive FDA approval expansion with...